Long COVID Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 65 years
- People who are able to make their own decisions and are willing to give written consent to participate, including consent for how their data is used
- People who have been diagnosed with depression of at least moderate severity (including depression as part of bipolar disorder), with a score of 20 or higher on a standard depression rating scale called the BDI-II
- People who also have a diagnosis of Post-COVID-19 condition (also known as Long COVID), as defined by the World Health Organization
- People whose depression has not improved enough despite taking medication for it
- People who have been on a stable, unchanged psychiatric medication for at least 4 weeks before the trial treatment begins
Who may not be able to join:
- People under 18 or over 65 years of age
- People who are pregnant, planning to become pregnant, or currently breastfeeding
- People who are under legal guardianship, or whose thinking or memory difficulties would prevent them from giving valid consent to participate
- People with a severe developmental disorder or significant intellectual disability
- People with a current or ongoing serious problem with alcohol, prescription drug misuse, or illicit drug use
- People currently being treated with a class of medications called benzodiazepines or Z-drugs (commonly used for anxiety or sleep)
- People who are currently at acute risk of suicide
- People who are currently experiencing psychotic symptoms (such as hallucinations or delusions)
- People with a serious neurological condition, such as a major brain injury or a neurodegenerative disease (confirm with trial site)
- People currently receiving another form of brain stimulation treatment, such as ECT, TMS, or VNS
- People for whom the brain stimulation technique used in this trial (TMS) would be unsafe, including those with metal implants in the skull, certain implanted medical devices (such as a cochlear implant, pacemaker, or implantable defibrillator), or a history of seizures or epilepsy-related brain activity on an EEG
- People with a serious medical illness, such as severe anaemia requiring a blood transfusion, serious heart rhythm problems, or a condition affecting the heart muscle (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Angelika Erhardt-Lehmann, MD, Prof., Max-Planck-Institute of Psychiatry
Phone: 0049-089-30622-1402
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in immunophenotypic marker CRP from baseline to post-treatment; Change in immunophenotypic marker TNF from baseline to post-treatment; Change in immunophenotypic marker IL-1ß from baseline to post-treatment; Change in immunophenotypic marker IL-6 from baseline to post-treatment; Total score change in the Becks Depression Inventory, version 2 (BDI-II, self-rating); Total score change in the clinician-rated Montgomery Asberg Depression scale (MADRS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.